Criteria to define HLA haplotype loss in human solid tumors.
Short tandem repeat (STR) markers are currently used to define loss of heterozygosity (LOH) of genes and chromosomes in tumors. Chromosome 6 and chromosome 15 STR markers are applied to define loss of HLA and related genes (e.g. TAP and beta2m). The number of STR identified in the HLA region is still increasing. In this study, seven representative STR markers covering the 6p/6q arms of chromosome 6 including the HLA region and two for chromosome 15 flanking the beta2m gene, were selected as minimally required for reliable LOH studies. A multiplex polymerase chain reaction (PCR) strategy is proposed when small number of cells are available in microdissected tumor samples.
Ramal
L M
LM
Department Analisis Clinicos, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Feenstra
M
M
van der Zwan
A W
AW
Collado
A
A
Lopez-Nevot
M A
MA
Tilanus
M
M
Garrido
F
F
D014408:Biomarkers, Tumor / Q000235:genetics* / Q000276:immunology; D002884:Chromosomes, Human, Pair 15; D002896:Chromosomes, Human, Pair 6; D006239:Haplotypes; D015395:Histocompatibility Antigens Class I / Q000235:genetics*; D006801:Humans; D019656:Loss of Heterozygosity / Q000235:genetics* / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D018895:Microsatellite Repeats; D010641:Phenotype; D016133:Polymerase Chain Reaction / Q000379:methods
D014408:Biomarkers, Tumor; D015395:Histocompatibility Antigens Class I